A new preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published in Nature ...
A groundbreaking study reveals that sacituzumab govitecan and pembrolizumab significantly enhance survival in untreated metastatic triple-negative breast cancer patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback